{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T22:59:22Z","timestamp":1771369162636,"version":"3.50.1"},"reference-count":50,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T00:00:00Z","timestamp":1649808000000},"content-version":"unspecified","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031936","name":"Moleac Pte Ltd","doi-asserted-by":"crossref","award":["The SAMURAI study is an industry-sponsored study f"],"award-info":[{"award-number":["The SAMURAI study is an industry-sponsored study f"]}],"id":[{"id":"10.13039\/100031936","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,3,22]]},"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Traumatic brain injury (TBI) is a leading cause of death in young adults globally and 90% of cases are mild TBI. Treatment to facilitate recovery after TBI is needed. Traditional medicine MLC901 (NeuroAiD II) with neuroprotective and neuroproliferative properties in cellular and animal models of brain injury showed TBI-associated cognitive improvement in mild or moderate TBI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analysis<\/jats:title>\n                  <jats:p>This is a randomised placebo-controlled trial, with 6-month treatment and 9-month follow-up, to determine the safety and efficacy of MLC901 in improving cognitive function in patients with cognitive impairment following mild TBI. This multicentre trial is conducted at the research centres of six hospitals\/institutions in Russia. The primary outcome is to determine the effect of MLC901 on complex attention using the CNS Vital Signs (CNS-VS) online neurological test after 6-month treatment in patients receiving MLC901 compared with placebo. Secondary outcomes include other cognitive domains of CNS-VS and Rivermead Post Concussion Symptoms Questionnaire. The exploratory endpoints include Quality of Life after Brain Injury, Hospital Anxiety and Depression Scale and evaluation of improved neurological parameters 3 months after treatment completion. In addition, treatment compliance, concomitant therapies and adverse events will be collected. Investigators will use a secured online system for data entry.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Ethics and dissemination<\/jats:title>\n                  <jats:p>The study has been approved by the ethic committee of Ministry of Health of the Russian Federation (No: 58074). The results of this study will be published in a peer-review journal and presented at international conferences as poster presentations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04861688\">NCT04861688<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-059167","type":"journal-article","created":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T13:43:14Z","timestamp":1649857394000},"page":"e059167","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Randomised, double-blind, placebo-controlled study investigating Safety and efficAcy of MLC901 in post-traUmatic bRAin Injury: the SAMURAI study protocol"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct04861688","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2168-9911","authenticated-orcid":false,"given":"Pavel","family":"Pilipenko","sequence":"first","affiliation":[{"name":"Department of Clinical Neurology and Neurogeriatrics, Novosibirsk State Medical University, Novosibirsk, Russian Federation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Andreevna","family":"Ivanova","sequence":"additional","affiliation":[{"name":"Adult Polyclinic Department N 124, State Budgetary Institution of Public Health City Polyclinic N 106, St. Petersburg, Russian Federation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulia Vadimovna","family":"Kotsiubinskaya","sequence":"additional","affiliation":[{"name":"Department of somatic diseases, X7 Research, St. Petersburg, Russian Federation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valery","family":"Feigin","sequence":"additional","affiliation":[{"name":"National institute for Stroke & Applied Neurosciences, Auckland University of Technology, Auckland, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Majdan","sequence":"additional","affiliation":[{"name":"Department of Public Health, Trnava University in Trnava, Trnava, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera Naumovna","family":"Grigoryeva","sequence":"additional","affiliation":[{"name":"Department of Nervous Diseases, Privolzhsky Research Medical University, Niznij Novgorod, Russian Federation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexey Yevgenievich","family":"Khrulev","sequence":"additional","affiliation":[{"name":"Department of Nervous Diseases, Privolzhsky Research Medical University, Niznij Novgorod, Russian Federation"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,4,13]]},"reference":[{"key":"2025101812293019000_12.4.e059167.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30371-X"},{"key":"2025101812293019000_12.4.e059167.2","doi-asserted-by":"publisher","DOI":"10.1097\/00001199-200609000-00001"},{"key":"2025101812293019000_12.4.e059167.3","doi-asserted-by":"publisher","DOI":"10.3233\/nre-2007-22502"},{"key":"2025101812293019000_12.4.e059167.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70262-4"},{"key":"2025101812293019000_12.4.e059167.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1992.tb10990.x"},{"key":"2025101812293019000_12.4.e059167.6","doi-asserted-by":"publisher","DOI":"10.1089\/neu.2013.2984"},{"key":"2025101812293019000_12.4.e059167.7","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp16X683161"},{"key":"2025101812293019000_12.4.e059167.8","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1227\/NEU.0000000000000292","article-title":"Elucidating the severity of preclinical traumatic brain injury models: a role for functional assessment?","volume":"74","author":"Turner","year":"2014","journal-title":"Neurosurgery"},{"key":"2025101812293019000_12.4.e059167.9","article-title":"Examining the correlation between acute behavioral manifestations of concussion and the underlying pathophysiology of chronic traumatic encephalopathy: a pilot study","volume":"6","author":"Byrd","year":"2018","journal-title":"J Neurol Psychol"},{"key":"2025101812293019000_12.4.e059167.10","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2015.00222","article-title":"The quest to model chronic traumatic encephalopathy: a multiple model and injury paradigm experience","volume":"6","author":"Turner","year":"2015","journal-title":"Front Neurol"},{"key":"2025101812293019000_12.4.e059167.11","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21393"},{"key":"2025101812293019000_12.4.e059167.12","doi-asserted-by":"publisher","DOI":"10.1097\/01.yco.0000165601.29047.ae"},{"key":"2025101812293019000_12.4.e059167.13","doi-asserted-by":"publisher","DOI":"10.1080\/02699050902748356"},{"key":"2025101812293019000_12.4.e059167.14","doi-asserted-by":"publisher","DOI":"10.1097\/TA.0b013e3181f2d670"},{"key":"2025101812293019000_12.4.e059167.15","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.108.531616"},{"key":"2025101812293019000_12.4.e059167.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2010.01.001"},{"key":"2025101812293019000_12.4.e059167.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2011.05.003"},{"key":"2025101812293019000_12.4.e059167.18","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neuroscience.2014.06.047","article-title":"MLC901, a traditional Chinese medicine induces neuroprotective and neuroregenerative benefits after traumatic brain injury in rats","volume":"277","author":"Quintard","year":"2014","journal-title":"Neuroscience"},{"key":"2025101812293019000_12.4.e059167.19","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-014-9570-0"},{"key":"2025101812293019000_12.4.e059167.20","doi-asserted-by":"publisher","DOI":"10.1159\/000126919"},{"key":"2025101812293019000_12.4.e059167.21","doi-asserted-by":"publisher","DOI":"10.1159\/000313398"},{"key":"2025101812293019000_12.4.e059167.22","doi-asserted-by":"publisher","DOI":"10.1159\/000247001"},{"key":"2025101812293019000_12.4.e059167.23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4061\/2011\/721613","article-title":"Safety and efficacy of MLC601 in Iranian patients after stroke: a double-blind, placebo-controlled clinical trial","volume":"2011","author":"Harandi","year":"2011","journal-title":"Stroke Res Treat"},{"key":"2025101812293019000_12.4.e059167.24","unstructured":"Kaishibayev S et al . Efficacy of NeuroAiD (MLC901) in combination therapy during early rehabilitation period of patients who had suffered an ischemic stroke."},{"key":"2025101812293019000_12.4.e059167.25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/1419720","article-title":"Predictors of neurological and functional recovery in patients with moderate to severe ischemic stroke: the EPICA study","volume":"2020","author":"Murie-Fern\u00e1ndez","year":"2020","journal-title":"Stroke Res Treat"},{"key":"2025101812293019000_12.4.e059167.26","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/ene.13653","article-title":"MLC901 (NeuroAiD II\u2122) for cognition after traumatic brain injury: a pilot randomized clinical trial","volume":"25","author":"Theadom","year":"2018","journal-title":"Eur J Neurol"},{"key":"2025101812293019000_12.4.e059167.27","first-page":"257","article-title":"MLC901 for moderate to severe traumatic brain injury: pilot, randomized, double-masked, placebo-controlled trial","volume":"2","author":"Hossein Pakdaman","year":"2020","journal-title":"Open Access Journal of Complementary & Alternative Medicine"},{"key":"2025101812293019000_12.4.e059167.28","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci10020060","article-title":"Clinical Outcomes of MLC601 (NeuroAiD\n                  TM\n               ) in Traumatic Brain Injury: A Pilot Study","volume":"10","author":"Fauzi","year":"2020","journal-title":"Brain Sci"},{"key":"2025101812293019000_12.4.e059167.29","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000346231","article-title":"Efficacy and safety of MLC601 (NeuroAiD\u00ae), a traditional Chinese medicine, in poststroke recovery: a systematic review","volume":"35 Suppl 1","author":"Siddiqui","year":"2013","journal-title":"Cerebrovasc Dis"},{"key":"2025101812293019000_12.4.e059167.30","first-page":"418","article-title":"NeuroAid (MLC601) versus piracetam in the recovery of post-infarct homonymous hemianopsia","volume":"6","author":"Ghandehari K","year":"2011","journal-title":"Neural Regeneration Research"},{"key":"2025101812293019000_12.4.e059167.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2011.01.002"},{"key":"2025101812293019000_12.4.e059167.32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1747-4949.2009.00237.x"},{"key":"2025101812293019000_12.4.e059167.33","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.113.002055"},{"key":"2025101812293019000_12.4.e059167.34","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/ijs.12324","article-title":"Baseline characteristics and treatment response of patients from the Philippines in the ChIMES study","volume":"9 Suppl A100","author":"Navarro","year":"2014","journal-title":"Int J Stroke"},{"key":"2025101812293019000_12.4.e059167.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.11.017"},{"key":"2025101812293019000_12.4.e059167.36","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.113.003226"},{"key":"2025101812293019000_12.4.e059167.37","doi-asserted-by":"publisher","DOI":"10.1159\/000382082"},{"key":"2025101812293019000_12.4.e059167.38","first-page":"1","article-title":"The use of NeuroAiD (MLC601) in postischemic stroke patients","volume":"2012","author":"Navarro","year":"2012","journal-title":"Rehabil Res Pract"},{"key":"2025101812293019000_12.4.e059167.39","doi-asserted-by":"publisher","DOI":"10.1159\/000155220"},{"key":"2025101812293019000_12.4.e059167.40","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1007\/s11655-014-1687-8","article-title":"A randomized trial to assess the long-term safety of NeuroAiD among Caucasian patients with acute ischemic stroke","volume":"20","author":"Bavarsad Shahripour","year":"2014","journal-title":"Chin J Integr Med"},{"key":"2025101812293019000_12.4.e059167.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.acn.2006.05.007"},{"key":"2025101812293019000_12.4.e059167.42","article-title":"A computerized test battery sensitive to mild and severe brain injury","volume":"10","author":"Gualtieri","year":"2008","journal-title":"Medscape J Med"},{"key":"2025101812293019000_12.4.e059167.43","unstructured":"Gualtieri CT , Johnson LG , Benedict KB . Psychometric and clinical properties of a new, computerized neurocognitive assessment battery. Bal Harbor, FL: American Neuropsychiatric Association Annual Meeting, 2004."},{"key":"2025101812293019000_12.4.e059167.44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/151379","article-title":"Cognitive impairment in relapsing remitting and secondary progressive multiple sclerosis patients: efficacy of a computerized cognitive screening battery","volume":"2014","author":"Papathanasiou","year":"2014","journal-title":"ISRN Neurol"},{"key":"2025101812293019000_12.4.e059167.45","doi-asserted-by":"publisher","DOI":"10.1191\/0269215505cr905oa"},{"key":"2025101812293019000_12.4.e059167.46","doi-asserted-by":"publisher","DOI":"10.1007\/BF00868811"},{"key":"2025101812293019000_12.4.e059167.47","doi-asserted-by":"publisher","DOI":"10.1089\/neu.2009.1077"},{"key":"2025101812293019000_12.4.e059167.48","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1983.tb09716.x"},{"key":"2025101812293019000_12.4.e059167.49","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3999(96)00216-4"},{"key":"2025101812293019000_12.4.e059167.50","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3999(01)00296-3"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-059167","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T19:29:41Z","timestamp":1760815781000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-059167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":50,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4,13]]},"published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1136\/bmjopen-2021-059167"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-059167","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4]]}}}